Bank of America’s Evelo Biosciences, Inc. Common Stock EVLO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-2,789
| Closed | -$10.9K | – | 8429 |
|
|
2023
Q3 | $10.9K | Buy |
2,789
+2,774
| +18,493% | +$18.9K | ﹤0.01% | 6838 |
|
|
2023
Q2 | $49 | Sell |
15
-2,526
| -99% | -$7.51K | ﹤0.01% | 7467 |
|
|
2023
Q1 | $9.15K | Buy |
2,541
+1,577
| +164% | +$24.3K | ﹤0.01% | 6938 |
|
|
2022
Q4 | $31K | Sell |
964
-1,471
| -60% | -$58.2K | ﹤0.01% | 6615 |
|
|
2022
Q3 | $102K | Buy |
2,435
+1,023
| +72% | +$46.8K | ﹤0.01% | 6342 |
|
|
2022
Q2 | $59K | Buy |
1,412
+604
| +75% | +$28K | ﹤0.01% | 6759 |
|
|
2022
Q1 | $55K | Sell |
808
-906
| -53% | -$75.4K | ﹤0.01% | 7145 |
|
|
2021
Q4 | $208K | Buy |
1,714
+1,366
| +393% | +$231K | ﹤0.01% | 6478 |
|
|
2021
Q3 | $49K | Buy |
348
+16
| +5% | +$3.17K | ﹤0.01% | 7066 |
|
|
2021
Q2 | $91K | Sell |
332
-1,303
| -80% | -$329K | ﹤0.01% | 6566 |
|
|
2021
Q1 | $350K | Buy |
1,635
+1,285
| +367% | +$355K | ﹤0.01% | 5650 |
|
|
2020
Q4 | $85K | Buy |
350
+135
| +63% | +$16.7K | ﹤0.01% | 6071 |
|
|
2020
Q3 | $23K | Sell |
215
-44
| -17% | -$4.01K | ﹤0.01% | 6259 |
|
|
2020
Q2 | $25K | Buy |
259
+90
| +53% | +$7.88K | ﹤0.01% | 6212 |
|
|
2020
Q1 | $13K | Sell |
169
-202
| -54% | -$19.2K | ﹤0.01% | 6299 |
|
|
2019
Q4 | $30K | Buy |
371
+8
| +2% | +$895 | ﹤0.01% | 6413 |
|
|
2019
Q3 | $45K | Buy |
363
+70
| +24% | +$9.62K | ﹤0.01% | 6359 |
|
|
2019
Q2 | $52K | Buy |
293
+147
| +101% | +$23.8K | ﹤0.01% | 6285 |
|
|
2019
Q1 | $22K | Sell |
146
-199
| -58% | -$39.4K | ﹤0.01% | 6483 |
|
|
2018
Q4 | $90K | Buy |
345
+293
| +563% | +$59K | ﹤0.01% | 5976 |
|
|
2018
Q3 | $13K | Buy |
52
+19
| +58% | +$4.97K | ﹤0.01% | 6604 |
|
|
2018
Q2 | $8K | Buy |
+33
| New | +$9.62K | ﹤0.01% | 6716 |
|
Other funds holding EVLO
Bank of America's EVLO Position: Q4 2023 in Review
Bank of America sold out of Evelo Biosciences, Inc. Common Stock (EVLO) in Q4 2023, closing a stake of 2,789 shares — an estimated $10.9K sold.
Bank of America first reported a position in EVLO in Q2 2018 and held it in 22 quarters. The position peaked at $350K in Q1 2021. 2 funds tracked by Wall St. Rank hold EVLO as of Q4 2023.
- Bank of America reported no remaining Evelo Biosciences, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
- Bank of America sold 2,789 Evelo Biosciences, Inc. Common Stock shares in Q4 2023, an estimated $10.9K.
- Bank of America first reported a position in Evelo Biosciences, Inc. Common Stock in Q2 2018 and held it in 22 quarters.
- Bank of America's Evelo Biosciences, Inc. Common Stock position peaked at $350K in Q1 2021.
- 2 funds tracked by Wall St. Rank held Evelo Biosciences, Inc. Common Stock as of Q4 2023.
Based on Bank of America's 13F filing for Q4 2023, filed 14 Feb 2024.